# Immunophenotypic Implications of Reverse-Circadian Glucocorticoid Treatment in Congenital Adrenal Hyperplasia

**Authors:** Hanna F. Nowotny, Hannah Choi, Selina Ziegler, Natalie Doll, Ariane Bäuerle, Ann-Christin Welp, Ilja Dubinski, Katharina Schiergens, Uta Neumann, Lea Tschaidse, Matthias K. Auer, Simon Rothenfusser, Heinrich Schmidt, Nicole Reisch

PMC · DOI: 10.3390/ijms26041479 · International Journal of Molecular Sciences · 2025-02-10

## TL;DR

This study compares two treatment approaches for a hormone disorder and finds differences in immune system effects.

## Contribution

The study reveals distinct immunological impacts of conventional versus reverse-circadian glucocorticoid treatment in congenital adrenal hyperplasia.

## Key findings

- Reverse-circadian treatment was associated with lower CD4+CD25+ T cells and reduced NK cell cytotoxicity.
- Switching from reverse-circadian to conventional treatment increased non-classical monocytes and decreased Th17 cells.
- Conventional treatment showed modest advantages in normalizing immune phenotypes compared to reverse-circadian treatment.

## Abstract

Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) requires lifelong glucocorticoid replacement to manage cortisol deficiency and excessive androgen production. Conventional circadian treatment (CT) tries to mimic natural cortisol rhythms, whereas reverse-circadian treatment (RC) prioritizes the suppression of adrenal androgen excess overnight through evening dosing. Limited data exist on the immunological impact of these regimens. A bi-centric study was conducted, including 41 pediatric and adolescent CAH patients. Peripheral blood samples were collected from patients on conventional treatment (n = 38) or RC (n = 16), with 11 RC patients switching to conventional treatment. Immune cell phenotypes, cytokine profiles, and natural killer (NK) cell cytotoxicity were assessed. Patients receiving RC showed lower percentages of CD4+CD25+ T cells (p = 0.0139). After the switch, patients with RC presented with a higher percentage of non-classical monocytes (p = 0.0255) and a lower percentage of Th17 cells (p = 0.0195). A lower expression of CD107 was observed with RC (p < 0.0001), as well as a higher percentage of NKp30 (p = 0.0189). Comparing patients after the switch from RC to HC, patients with RC presented with a lower NKG2D expression (p = 0.0420). Both conventional treatment and RC exhibited distinct immunological impacts, with CT showing modest advantages in normalizing immune phenotypes. These findings suggest that CT may offer immunological benefits for managing young patients with congenital adrenal hyperplasia.

## Linked entities

- **Proteins:** CD4 (CD4 molecule), IL2RA (interleukin 2 receptor subunit alpha), NCR3 (natural cytotoxicity triggering receptor 3), KLRK1 (killer cell lectin like receptor K1)
- **Diseases:** congenital adrenal hyperplasia (MONDO:0015898)

## Full-text entities

- **Genes:** KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, NCR3 (natural cytotoxicity triggering receptor 3) [NCBI Gene 259197] {aka 1C7, CD337, LY117, MALS, NKp30}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** adrenal androgen excess (MESH:D014770), Congenital Adrenal Hyperplasia (MESH:D000312), 21-hydroxylase deficiency (MESH:C535979), cortisol deficiency (MESH:C535280)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11855454/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11855454/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC11855454/full.md

---
Source: https://tomesphere.com/paper/PMC11855454